Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.05% | -281.32% | 10.82% | 10.49% | -120.09% |
| Total Depreciation and Amortization | 0.30% | -10.69% | -18.68% | 16.39% | -10.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 74.02% | 44.25% | -65.86% | 66.10% | 114.46% |
| Change in Net Operating Assets | -170.78% | 177.20% | 21.13% | -141.44% | 179.91% |
| Cash from Operations | -160.82% | 48.05% | 11.44% | -153.74% | 347.34% |
| Capital Expenditure | -324.52% | 39.92% | 73.32% | 54.83% | -183.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 254.76% | -141.86% | 284.73% | 62.76% | -440.45% |
| Cash from Investing | 251.46% | -142.27% | 279.04% | 62.58% | -458.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.71% | 4,000.00% | -97.55% | -99.49% | 24,433.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -85.71% | 4,000.00% | -97.55% | -99.49% | 24,433.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.23% | -213.08% | 154.36% | -188.61% | 2,038.64% |